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Benefit from high intrarenal levels of gentamicin in the treatment of
E. co/i pyelonephritis. The importance of high intrarenal levels of
gentamicin on the outcome of experimental pyelonephritis was studied
in rats receiving either a short course (three days) of gentamicin (G)
alone or combined with a longer course (14 days) of ampicillin (A),
cephalothin (C), or trimethoprim (T), or two weeks of therapy with
ampicillin, cephalothin, trimethoprim and gentamicin given alone.
While ampicillin, cephalothin and trimethoprim were undetectable in
the medulla within six hours of cessation of therapy, gentamicin was
still detectable in levels six folds above the MIC up to six months after
treatment had ceased. Six months after the end of treatment, the
percentage of sterile left kidneys in animals treated with ampicillin
(50%), cephalothin (15%), trimethoprim (20%) was lower than the
percentage of animals receiving 14 days of gentamicin (100%), or the
combinations AG:89%, CG:67% and TG:60%, P < 0.01. Following
three days of gentamicin, 50% of the left kidneys were sterilized. When
compared to ampicillin, cephalothin or trimethoprim alone, combined
therapies significantly reduced the number of CFU in the kidneys P <
0.01. These combinations were almost as effective as two weeks of
therapy with gentamicin. Short—term therapy (three days) with an
aminoglycoside which concentrates in the renal parenchyma, combined
with an antibiotic which will accumulate in other parts of the nephron,
may result in "pharmacological synergy". This new approach to
therapy of pyelonephritis may be promising.
In the last ten years, new approaches to the management of
lower urinary tract infections have been evaluated, but no
major innovation has been suggested for the treatment of
pyelonephritis. The unique capacity of gentamicin and other
aminoglycosides to accumulate within the kidneys of humans
and animals has been known for many years [1, 21, but only in
rare instances have investigators tried to study the pharmaco-
kinetic behavior of these antibiotics in infected renal paren-
chyma [3], or to correlate intrarenal distribution of these
antibiotics with their therapeutic efficacy in pyelonephritis
[4—6]. Previous investigations have revealed that gentamicin
appeared to be superior to ampicillin and trimethoprim—sulfa-
methoxazole in the treatment of experimental pyelonephritis
[7]. More so, several studies have recently described the
remarkable efficacy of gentamicin used in combination with
ampicillin [7, 81 in renal infections.
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The purpose of the present study was to evaluate, over a
period of six months, the intrarenal distribution and the com-
parative efficacy of short and long—term therapy with ampicillin,
cephalothin, trimethoprim, and gentamicin administered alone
or in combination for the treatment of acute pyelonephritis in
rats.
Methods
Animal experiments
Female Sprague—Dawley rats weighing 175 to 200 g were used
for all experiments. Pyelonephritis was induced by direct injec-
tion of the left kidney with 0.1 ml of an inoculum containing iO
to 108 CFU of Escherichia co/i Yale strain [5]. The bacteria
were injected directly into the medulla through the upper and
lower poles of the kidney, as described by Kaye [9]. This
inoculation produced two kinds of infection: a severe pyelone-
phritis of the left kidney, with extensive inflammation and
abscess formation induced by the inoculation, and a less severe
pyelonephritis of the right kidney, with few foci of inflammation
and slight swelling of the organ due to reflux of infected urine
into the right ureter and kidney, rats being naturally prone to
vesico-ureteral reflux. Treatment was started 24 hours after
inoculation and the rats were divided into eight groups. The
amount of drug given was based on previous observations in
rats which demonstrated that the doses given resulted in serum
concentrations which were considered as "equivalent" to those
observed in humans. Eight groups of 50 to 55 rats were given
the therapeutic regimens summarized in Table 1. In each group,
2/3 of the animals were evaluated for bacterial outcome while
1/3 were used to determine the concentration of drugs in the
kidney parenchyma. Rats were sacrificed at 1, 2, 4, 6, 24 hours
and on day 25, and six months after therapy.
Rats were anaesthetized with pentobarbital (dose, 50 mg/kg)
75 minutes before sacrifice. Fifteen minutes after the anaesthe-
sia, the bladder was emptied by suprapubic puncture. When the
animals were killed, the urine from each animal was collected
for determination of drug concentration and bacterial content.
Then, a midline abdominal incision was made and both kidneys
were extracted. The kidneys used to determine drug concentra-
tions were removed from their capsule and slit by a longitudinal
incision. Under a dissecting microscope, the kidneys were
separated into cortical, medullary, and papillary components.
Each entire cortex, medulla and papilla was weighed individu-
ally, diluted in a volume of phosphate buffer solution three
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Ampicillin 100 mg/kg Q6H 14 days
Cephalothin 50 mg/kg Q6H 14 days
Trimethoprim 10 mg/kg QI2H 14 days
Gentamicin 10 mg/kg Q12H 14 days
Gentamicin 10 mg/kg Q8H 3 days
Ampicillin— tOO mg/kg Q6H—lO mg/kg Q8H 14 days—3 days
Gentamicin
Cephalothin— 50 mg/kg Q6H 10 mg/kg Q8H 14 days—3 days
Gentamicin
Trimethoprim— 10 mg/kg Q12H—10 mg/kg Q8H 14 days—3 days
Gentamicin
Controls 0.9 NaC1 14 days
times the weight of the cortex and medulla and 12 times that of
the papilla (pH 7.4), and homogenized at 4°C with a Dyna-Mix
homogenizer (Fisher Scientific, Pittsburgh, Pennsylvania,
USA). Once homogenized, the samples were analyzed for
concentrations of ampicillin, cephalothin, trimethoprim, and
gentamicin. The kidneys used for bacterial counts were also
removed from their capsule but not dissected into cortex,
medulla and papilla. The kidneys were homogenized in 3 ml of
0.9% NaC1 with the use of the Dyna-Mix homogenizer (Fisher);
the number of E. coli present in each sample was then deter-
mined.
Drug levels
The concentrations of ampicillin [5], cephalothin, trimetho-
prim FbI, and gentamicin [61 were estimated as described
before in the serum, urine, cortex, medulla, and papilla. Con-
centrations were determined with the use of a standard
filter—paper disk agar diffusion assay [2]. Standard solutions
were prepared in serum for assays of drug in serum, in 0.9%
NaCI for urine, and in homogenates of cortex, medulla, and
papilla for renal tissue. The determination of ampicillin, ceph-
alothin, and gentamicin was made on Tryptic Soy Agar inocu-
lated with Bacillus subtilis as the test organism, and trimetho-
prim was determined on Iso-Sensitest Agar inoculated with
Bacillus pumilus.
Recovery of the antimicrobial agents, after the addition of
drug—free homogenates of cortex, medulla, and papilla to
known concentrations of antibiotics was 94 6% for ampicillin,
91 4.3% for cephalothin, 93 6% for trimethoprim, and 98
1.6% for gentamicin (mean SEM).
Efficacy in vitro
For the strain of E. coli used, the M1Cs in jsg/ml were 3.9 for
ampicillin, 6.2 for cephalothin, 0.35 for trimethoprim, and 1.6
for gentamicin. Time—killing curve technique [11] was used to
determine whether or not ampicillin, cephalothin, and trimeth-
oprim were synergistic when combined with gentamicin. An
overnight inoculum of E. co/i Yale strain was diluted to l0 to
106 organisms per ml with Mueller Hinton Broth. Antibiotics
were added to make a final concentration of one half the MIC
for each drug, Undiluted or diluted samples were removed
initially and at 1, 2, 4, 6, and 24 hours plated on MacConkey
agar, and incubated at 37°C. Colony counts were performed 24
hours after incubation. Synergy was defined as > 100-fold
increased killing at 24 hours by both drugs, as compared to the
single most effective drug alone.
Efficacy in viva
Appropriate dilutions of urine and homogenized kidneys
were made, and 0.1 ml of the sample was placed in each of three
pour plates containing MacConkey's agar. The number of CFU
of E. coli in the urine and kidneys was determined after an
incubation of 18 hr at 37°C. To prevent the inhibition of growth
that could occur if gentamicin was still present in the tissue,
sodium polyanetholsulfonate (2.0%), was added to the pour
plates. This compound could inhibit more than 1,200 sg of
gentamicin/g of tissue in the renal homogenate. This technique
allowed us to detect a minimum of 10 CFU/ml of urine and 30
CFU/g of renal tissue. Urine specimens or kidneys were con-
sidered sterile if no CFU was detected by this technique.
Statistical methods
Statistical comparison of the incidence of sterilization be-
tween single and combination therapy was done by means of
the .k2 test with Yates' correction. The differences in the log
number of CFU/g of tissue in the kidneys between single
therapies and their respective combinations were compared for
significance by Mann—Whitney test using normal two—tail ap-
proximation.
Results
Renal levels of antibiotics
The concentrations of ampicillin, cephalothin, trimethoprim,
and gentamicin in the cortex, medulla, and papilla of infected
kidneys are shown in Figure 1. Gentamicin was still detectable
in the medulla up to six months after two weeks of therapy, and
up to 25 days following 3 days of treatment. Ampicillin,
cephalothin, and trimethoprim could not be detected in the
infected cortex and medulla for more than six hours. With the
exception of trimethoprim which was still detectable in the
cortex at six hours, both cephalothin and ampicillin were below
MIC within four hours of the injection. Furthermore, with the
exception of gentamicin given for 14 days, none of the drugs
was detectable in the papilla 24 hours after the last injection.
The concentrations of gentamicin in the papilla were always
lower than those found in the cortex and medulla.
As shown in Table 2, serum levels were equivalent to those
observed in humans. At six hours, none of the serum had any
demonstrable antibiotic activity. Urinary levels of ampicillin,
cephalothin, and trimethoprim were undetectable at 24 hours
after cessation of therapy while high levels of gentamicin were
still detectable at that time. The ratios of the concentrations of
drug in the cortex and the medulla to the respective MICs of the
antimicrobial agents against the E. coli are presented in Figure
2. Gentamicin and trimethoprim exhibited higher peak ratios in
the kidney than ampicillin and cephalothin. The time during
which the E. co/i in the kidney was exposed to significant
concentrations of drugs can be observed in Figure 2. Following
14 days of gentainicin, the bacteria were continuously exposed
to the drug for more than six months after the end of treatment.
More so, both in the cortex and the medulla, E. co/i was
exposed to concentrations above MIC for at least 25 days
Table 1. Treatment regimen given 24 hours after the induction of
pyelonephritis due to E. coli in rats
Treatment Dose Time
Fig. 1. Concentrations of gentamicin,
ampicillin, cephalothin, and trimethoprim in
the cortex, medulla and papilla of
pyelonephritic kidneys due to Escherichia coli.
Concentrations were determined from 1 hr to
six months after cessation of therapy. The
mean SEM values of five animals are indi-
cated for each interval. Symbols are: (U—•)
G14: gentamicin 14 days; (U--Lu)
G3:gentamicin 3 days; (•—•) A: ampicillin;
(A-•-A) C: cephalothin; (O---O) T:
trimethoprim.
Drug, length
of
treatment'
Serum 1evels (g/ml)
1 hr
Urmary levels (pg/ml)
2 hr 4 hr 6 hr 24 hr 25 day1 hr 2 hr 4 hr 6 hr 24 hr
Ampicillin 39.0 (1.7) 7.4 (2.7) <0.5 <0.5 <0.5 18220 (555) 6760 (518) 33.6 (9.6) 25.0 (20.9) <0.5 <0.5
Cephalothin 22.8 (2.5) 0.4 (0.4) <0.5 <0.5 <0.5 4125 (354.4) 770.0 (18.9) 2.7 (2.3) 0.5 (0.4) <0.5 <0.5
Trimethoprim 1.5 (0.1) 0.4 (0.2) <0.5 <0.5 <0.5 742 (55.7) 773.3 (34.0) 94.0 (13.1) 24.0 (1.0) <0.5 <0.5
Gentamicin 10.2 (3.6) 2.8 (0.9) 0.5 (0.5) N.D.C <0.5 2556 (877) 2002 (625) 130.8 (40.0) N.D. 6.4 (1.3) <0.5
(3 days)
Gentamicin 11.5 (0.34) 1.0 (0.1) <0.5 N.D. <0.5 2983 (157.9) 723.3 (57.3) 230.0 (44.7) N.D. N.D. <0.5
(14 days)
a Numbers indicate mean g/ml (± SEM).
b See Table 1 for description of dosages given.
a ND. No data.
following cessation of therapy with the short course (three
days) of gentamicin. Following treatments with ampicillin and
cephalothin, the respective daily exposures of the bacteria to
the drugs were 8 and 7.2 hours, while trimethoprim was found
above MIC for over 12 hours each day of treatment.
In vivo efficacy
Table 3 represents the percentage of left kidneys and urine
sterilized on day one, 25 and at 6 months following cessation of
therapy. An animal was considered cured if, after appropriate
dilutions, no bacteria could be detected in the left kidney and
urine. Ampicillin, cephalothin, trimethoprim, and gentamicin
(three days) administered alone exhibited little activity in the
left kidneys for the first 25 days. At six months, gentamicin used
alone for three days was more effective than single therapy with
TMP and cephalothin. Fourteen days of gentamicin was the
most effective regimen (P < 0.01) with 100% of animals cured
25 days and six months after cessation of therapy. Six months
after the end of treatment, the percentage of sterile left kidneys
in animals treated with ampicillin (50%), cephalothin (15%), and
trimethoprim (20%) was lower (P < 0.01) than the percentage of
animals receiving the combinations AG:89%, CG:67%, and
TG:60%. Twenty—five days after the treatment had ceased, the
combination gentamicin plus trimethoprim was the most effec-
tive combination P < 0.03. Gentamicin plus ampicillin was the
best combination at six months. In the urine, therapy with
ampicillin or trimethoprim, and three days of gentamicin alone,
respectively eradicated the bacteria in 50%, 50%, and 44% of
rats at six months, while cephalothin did sterilize the urine in
23% of the animals. Gentamicin administered for 14 days
sterilized all urine. The combinations were also very effective at
days one, 25, and six months, except for the combination
gentamicin plus cephalothin where at 25 days and six months,
44% and 56% of urine were found to be sterile. Whereas 100%
of animals that were used as controls at each time interval still
had infected left kidneys, 17% of rats evaluated at six months
had sterile urine.
The mean log numbers of CFU of E. coli/g of tissue in the left
kidneys of rats evaluated at one and 25 days and at six months
after cessation of therapy are expressed in Figure 3. When
compared with ampicillin, cephalothin, or trimethoprim given
alone, combined therapies significantly reduced the number of
Cortex
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Table 2. Concentrations of antimicrobial agents in serum and urine of infected rats after the last injectiona
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potential and still benefit from the unique intrarenal pharmaco-
logical properties and therapeutic advantage of this aminoglyco-
side.
Several models of experimental pyelonephritis have been
used to evaluate the efficacy of antimicrobial agents in this type
of infection [12—14], but in most studies [4, 8, 15, 16], the
animals were followed for a short period (three weeks) and in
many instances, a significant number of animals did recover
spontaneously from their infection. In the present experiment,
the model of direct inoculation was used because it has the
advantage of inducing bilateral pyelonephritis, which can be
maintained in almost 100% of the animals for a period of up to
one year after inoculation [3]. The present study also stresses
the fact that urine may be sterile in the face of severe pyelone-
phritis. In fact, 17% of the control animals had sterile urine
while lOt)% of the kidneys were infected.
As we have previously shown [31, the results of our pyelo-
nephritis experiments clearly demonstrate that effective levels
of gentamicin could be maintained continuously within the
infected renal parenchyma of rats up to six months after two
weeks of therapy and more than 25 days when the aminoglyco-
side was administered for only three days. Aminoglycosides,
especially gentamicin, have been known to accumulate in the
kidneys of humans [17], and animals [181, hut only in rare
instances have investigators tried to correlate intrarenal distri-
bution of antimicrobial agents with the efficacy in pyelonephri-
tis [4, 7]. Glauser, Lyons and Braude [191 have shown that the
development of pyelonephritis in rats can be prevented as long
as aminoglycosides are administered before the induction of
pyelonephritis. Miller, Phillips and North [4], using a slightly
different animal model, have also described a reciprocal rela-
tionship between the concentrations of gentamicin in the cortex
and medulla and the persistance of bacteria, but they have not
eliminated, as we did by the use of sodium polyanethol sulfo-
nate, the presence of aminoglycosides in the tissue which might
have interfered with colony counts. The superiority of our
therapeutic regimens might be explained by the fact that Miller
et al administered gentamicin as a single dose for Il days while
multiple injections were used in the present study. It is known
that the cumulation kinetics of gentamicin can be affected by
mode of administration, and that single daily dose results in
lower levels of aminoglycoside in the kidney than multiple daily
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Fig. 2. Ratio of the concentration of antimicrobial agents in the cortex
and the medulla of kidneys/the MJC for the infecting strain of Esche.
richia co/i after cessation of therapy with either ampicillin, cephalothin,
trimethopritn, gentamicin fr 3 days, or gentomicin for 14 days. The
mean values for five animals are indicated for each time interval.
Symbols are the same as Figure 1.
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kidneys of rats evaluated on days I and 25, and 6 months after the end
of each therapeutic regimen.
CFU in the kidneys (P < 0.01). These combinations were as
effective as two weeks of therapy with gentamicin. Gentamicin
administered alone for three days reduced significantly the
mean number of bacteria from 1058CFU at one day to less than
10 at six months. A reduction in the number of CFU over the
six month period was also observed in the controls.
In vitro synergism
The rate of killing of E. coli Yale strain by ampicillin,
ccphalothin and trimethoprim alone, or in combination with
gentamicin is represented in Figure 4. Synergism against E.coli
was demonstrated between ampicillin and gentamicin. Cepha-
lothin and trimethoprim in combination with gentarnicin did not
show any synergism.
Discussion
The results of the present investigation demonstrate that
gentamicin, which accumulates within the renal parenchyma,
was more effective than ampicillin, cephaloihin, and trimetho-
prim in the treatment of severe pyelonephritis. When
gentamicin was combined with ampicillin, cephalothin, or tn-
methoprim, we could reduce the duration of therapy with
gentamicin to three days, thereby diminishing its nephrotoxic
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Table 3. Percentage (%) of left kidneys and urine sterilized one, 25 days, and six months after cessation of therapy.
Treatment
regimen, days
Left kidneys
—
Urine
1 day 25 days 6 months 1 day 25 days 6 months
Controls, 14 0/12 (0%) 0/12 (0%) 0/12 (0%) 0/12 (0%) 0/12 (0%) 2/12 (17%)
Ampicillin, 14 0/9 (0%) 2/10 (20%) 5/10 (50%) 4/10 (40%) 6/10 (60%) 5/10 (50%)
Cephalothin, 14 1/12 (8%) 3/13 (23%) 2/13 (15%) 1/12 (8%) 1/13 (8%) 3/13 (23%)
Trimethoprim, 14 1/10 (10%) 3/11 (27%) 2/10 (20%) 0/10(0%) 2/11 (18%) 5/10 (50%)
Gentamicin, 3 0/9 (0%) 3/8 (37%) 4/8 (50%) 8/10 (80%) 4/9 (44%) 4/9 (44%)
Gentamicin, 14 4/6 (67%) 6/6 (100%) 6/6 (100%) 6/6 (100%) 6/6 (100%) 6/6 (100%)
A + G3 4/8 (50%) 4/8 (50%) 8/9 (89%) 8/9 (89%) 8/9 (89%) 8/9 (89%)
C + G3 7/9 (78%) 3/9 (33%) 6/9 (67%) 8/9 (89%) 4/9 (44%) 5/9 (56%)
T + G3 8/10 (80%) 9/11(82%) 6/10 (60%) 9/10 (90%) 8/11(73%) 7/10 (70%)
Abbreviations are: A, 14 days ampicillin; C, 14 days cephalothin; T, 14 days trimethoprim; and G3, 3 days gentamicin
injections [20]. In fact, the renal levels observed in our study
were much higher than those of Miller et al [41.
The intrarenal pharmacokinetics of ampicillin, cephalothin,
and trimethoprim was quite different from that of gentamicin
and they could not be maintained in tissues at levels above MIC
for more than six hours after the injection. As demonstrated in
normal animals [10, 21], trimethoprim could concentrate in all
parts of the infected kidney at levels 170 times higher than those
of serum and 500 times above the MIC of the E. co/i, while the
medullary levels of ampicillin and cephalothin were found to be
less than three times higher than the serum levels but still 30
times above the MIC.
The reasons for such high failure rate in the kidneys of
animals treated with ampicillin, cephalothin, and trimethoprim
in the presence of high levels of drugs within the urine and renal
parenchyma are not entirely clear. The above data suggest that
the mere detection of high concentrations of antibiotics in the
infected renal tissue does not necessarily imply that these levels
are effective in vivo [22, 231. These results can most likely be
explained by the incapacity of the agents to reach bacteria
sequestered within the infected renal parenchyma and the rapid
regrowth of bacteria due to the short tissue half lives of the
antibiotics.
Although ampicillin, cephalothin, and trimethoprim did not
sterilize more than 50% of the severely infected left kidney after
six months of follow—up, the number of CFU within the
parenchyma was reduced when compared with the controls.
Our results are in accordance with those of other investigators
who have observed a 100-fold reduction in the number of CFU
after therapy with either ampicillin or cephalothin for the
treatment of enterococcal or E. co/i pyelonephritis [8, 24, 25].
The marked reduction in the CFU of E. coli in the animals
treated with three days of gentamicin and the complete steril-
ization of the kidneys after 14 days of gentamicin further stress
the fact that the long phase of aminoglyco side retention in the
kidney might be beneficial and that sufficient free gentamicin
might be available in the infected parenchyma to sterilize the
kidney. Local inactivation of gentamicin by its binding to either
pus cells from the infected kidney [26], or renal tissues [27]
could also explain the limited efficacy of gentamicin when given
for only three days. The 45% binding of trimethoprim to
medullary cells [10] might also have affected its local activity.
This binding was not as striking with ampicillin (10%) [5], and
cephalothin (10%) (unpublished data). More so, the electrolyte
content and osmolality of medullary tissue fluid, which are
similar to those observed in concentrated urine could have
reduced the activity of gentamicin [281. We cannot exclude
factors such as the inflammatory process which may have
modified vascular permeability and limited the accessibility of
the antibiotics to the infected site. Finally, one may speculate
that the overall poor efficacy of cephalothin might be partially
explained by its conversion into desacetylcephalothin [291. In
fact, we have shown in rabbits that the metabolite of cephalo-
thin (desacetylcephalothin) contributes to 75% of plasma con-
centrations. Cabana et al [30] have also shown that the metab-
olite of cephapirin (desacetylcephapirin) contributes to 75% of
plasma concentration in rats. If cephalothin is metabolized to
such an extent in rats, it could certainly have affected the
activity of cephalothin in the treatment of pyelonephritis.
The remarkable efficacy of ampicillin, cephalothin, and tn-
methoprim in combination with gentamicin observed in our
study is in accordance with past observations which have
shown that combination therapy is more effective than single
drug regimen. McCabe and Jackson [31] have also found that
combinations of drugs that were synergistic in vitro were more
effective in humans than combinations that were not synergistic
in vitro; but in several of their patients treated with synergistic
combinations, the infection recurred. Glauser et al have de-
scribed the great efficacy of the combination of gentamicin with
ampicillin [81 or ceftriaxone [161 in the treatment of experimen-
tal pyelonephritis. We have also observed the same efficacy of
the combination gentamicin—ampicillin in a different type of
experiment [7].
Although several factors may have contributed to the supe-
riority of the combinations over single therapy, we can evoke,
at least for the combination ampicillin plus gentamicin, the
possibility that this combination, which was shown to be
synergistic in vitro, might have resulted in in vivo synergism.
This does not seem to be the case with the combinations
cephalothin plus gentamicin and trimethopnim plus gentamicin
where no in vitro synergism could be demonstrated. To explain
this in vivo synergism, we believe that the combined drugs are
working at different sites in the infected renal parenchyma,
resulting in what we term pharmacological synergy. By reduc-
ing substantially the number of CFU in the kidney, combined
therapy could have diminished the inflammatory process rap-
idly and thus allowed a better diffusion of the antimicrobials at
the site of infection, resulting in a better therapeutic response.
Our data also suggest that though the MIC of the antibiotics
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studied against the E. coli varied enormously from one drug to
the other, it did not seem to influence the outcome of therapy.
Continuously maintained bactericidal levels are usually re-
quired to achieve cure in cases of severe infections, such as
bacterial endocarditis [32], or of infections in neutropenic
patients [33], for whom host defenses may not necessarily
operate in conjunction with the antimicrobial agents. From our
results, it appears that, in the presence of severe pyelonephritis,
it may be necessary to maintain effective levels of antibiotics for
a considerable period of time in order to achieve a therapeutic
effect. More so, the addition of another antimicrobial agent
further enhanced the effectiveness of gentamicin. The mere
finding that the above combinations could sterilize the left
kidney, where the severity of the infection is extreme, suggests
that three days of i.v. gentamicin, or other aminoglycosides, in
combination with either ampicillin, a cephalosporin, or trimeth-
oprim, followed by two weeks of oral therapy with non-ami-
noglyeoside drugs should be further evaluated in the treatment
of severe pyelonephritis in humans.
The pharmacologic and therapeutic advantage of aminogly-
cosides, especially gentamicin, has to be weighed against its
potential nephrotoxicity. Recent studies from our laboratory
suggest that pyelonephritic kidneys are more susceptible to
aminoglycosides than the normal kidneys [34]. By reducing the
number of days of treatment with aminoglycosides, we can
shorten hospitalization and reduce the oto and nephrotoxic
potential of these drugs while benefiting from their unique
intrarenal pharmacological properties.
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